In a sweeping internal reform, the U.S. Food and Drug Administration (FDA) has launched its first agency-wide deployment of artificial intelligence for drug review. Last Friday, Commissioner Dr. Martin Makary announced that all FDA centers must “aggressively” and “immediately” integrate generative AI by June 30, following the agency’s first pilot review using the technology. “I …

The post FDA Deploying AI to Accelerate Drug Approvals appeared first on The New American.